Abstract Number: 1070 • 2016 ACR/ARHP Annual Meeting
Performance and External Validation of the Damage Index in Antiphospholipid Syndrome in Primary and Secondary APS Patients
Background/Purpose: In APS, irreversible organ damage may result of disease activity, medications, or comorbid illnesses. To assess it, different methods have been used including the…Abstract Number: 1071 • 2016 ACR/ARHP Annual Meeting
Anti-β2GP-I-Domain 3 and Aps/PT-IgG Antibodies Identify Primary APS Patients with Both Thrombotic and Hematological Manifestations
Background/Purpose: Thrombocytopenia and hemolytic anemia (HA) are considered non-criteria clinical manifestations by the Sydney revised criteria for APS. These features can precede, follow a thrombotic…Abstract Number: 1072 • 2016 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking Registry Analysis: Cardiovascular Risk Factors Among Different Groups of Antiphospholipid Antibody-Positive Patients
Background/Purpose: Traditional cardiovascular disease (CVD) risk factors increase the risk of thrombotic clinical manifestations in antiphospholipid antibody (aPL)-positive patients. The prevalence of CVD risk factors…Abstract Number: 1073 • 2016 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking (APS ACTION) Clinical Database and Repository Analysis: The Comparison of Real World and Core Laboratory Antiphospholipid Antibody ELISA Results
Background/Purpose: The APS ACTION International Clinical Database and Repository (“Registry”) was created to study the natural course of disease over 10 years in persistently aPL-positive…Abstract Number: 1074 • 2016 ACR/ARHP Annual Meeting
The Risk of Obstetric Complications and the Effects of Treatment in Women with Low Titer and Medium-High Titer Anti-Phospholipid Antibodies
Background/Purpose: The association of low titer anti-phospholipid antibodies (aPL) with obstetric anti-phospholipid syndrome (APS) is increasingly acknowledged, even though some studies have showed conflicting results.…Abstract Number: 1075 • 2016 ACR/ARHP Annual Meeting
CD40-Pathway Activation in Ectopic Lymphoid Structure (ELS)-Resident B Cells Contributes to Disease Pathology in Primary SjöGren’s Syndrome
Background/Purpose: T cell-dependent activation of B lymphocytes is a key effector arm of the adaptive immune system, resulting in protective antibody responses and long-lived humoral…Abstract Number: 1076 • 2016 ACR/ARHP Annual Meeting
BAFF Receptor Antagonists Suppress Differentiation of B Cells in Vitro and Are Drug Candidates for Primary SjöGren’s Syndrome
Background/Purpose: We have reported that soluble BAFF (sBAFF) robustly increases IL-6 production in vitro by peripheral monocytes of patients with primary Sjögren’s syndrome (pSS) as…Abstract Number: 1077 • 2016 ACR/ARHP Annual Meeting
Increased Expression of B-Cell Lipid Rafts in Patients with Primary Sjogren’s Syndrome Correlated Positively with Disease Activity Score, Suggesting a B Cell Activated State Potentially Relevant for the Disease Pathogenesis and Response to Biologic Therapies
Background/Purpose: Recent research indicates that lipid rafts play an important role during B-cell activation and could be defective in patients with primary Sjӧgren’s syndrome (pSS).…Abstract Number: 1078 • 2016 ACR/ARHP Annual Meeting
Elevated Proportion of CD38highIgD+ b Cells in Peripheral Blood Is Related to Disease Activity in Patients with Primary SjöGren’s Syndrome
Background/Purpose: Primary Sjögren’s syndrome (pSS) is well recognized as an autoimmune disease accompanied by hypergammaglobulinemia and production of autoantibodies such as anti-Ro/SSA and anti-La/SSB antibodies.…Abstract Number: 1079 • 2016 ACR/ARHP Annual Meeting
Discovery of Novel Autoantigens in Sjogren’s Syndrome with Potential for Subgrouping of Disease
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a common autoimmune disease with exocrine gland dysfunction and multi-organ involvement. With the growing interest in conducting clinical trials…Abstract Number: 1080 • 2016 ACR/ARHP Annual Meeting
B-Cell Clonal Expansions in Parotid Glands of Sjogren’s Patients Are Associated with Increased Numbers of N-Glycosylation Motifs in the Immunoglobulin Heavy Chain Genes
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease characterized by chronic inflammation of salivary and lacrimal glands. Patients with pSS have increased clonal…Abstract Number: 1081 • 2016 ACR/ARHP Annual Meeting
The CRL4CRBN E3 Ubiquitin Ligase Modulator CC-220 Inhibits BAFF-Mediated Plasmablast Differentiation and Immunoglobulin Secretion from Class Switched CD27+IgD- Memory and Lupus-Associated CD27-IgD- Double Negative B-Cells
Background/Purpose: Changes in the ratio of circulating memory, naive, and double negative CD27-IgD- B cell subsets are associated with a higher disease activity index in…Abstract Number: 1082 • 2016 ACR/ARHP Annual Meeting
Type I/II Interferon Commits to Abnormal Expression of Chemokine Receptor on B Cells in Patients with Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by an expanded population of peripheral memory B cells. However, little is known about the qualitative abnormality of…Abstract Number: 1083 • 2016 ACR/ARHP Annual Meeting
Discovery and Subsequent Diagnostic Verification of Autoantibodies Against the Major Vault Protein (MVP) in Systemic Lupus Erythematosus
Background/Purpose: In systemic lupus erythematosus (SLE), early diagnosis and prognostic stratification are still great challenges. The broad characterization of the autoantibody repertoire in SLE is…Abstract Number: 1084 • 2016 ACR/ARHP Annual Meeting
Antibodies to Native Vimentin in Lupus: Characterization, Isotypes, Origins, and Associations with Other Autoimmune Pathways
Background/Purpose: Severe lupus tubulointerstitial nephritis (TIN) is prognostic of renal failure and characterized by tertiary lymphoid organogenesis. We have previously demonstrated that the dominant target…
ACR Meeting Abstracts